Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market…
contravirDecember 7, 2023
EDISON, N.J., Jan. 06, 2022 -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis…
contravirJanuary 6, 2022
EDISON, NJ / August 27, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) "Hepion", a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from…
contravirAugust 27, 2020